Literature DB >> 23836900

Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors.

Vanessa Vezzi1, H Ongun Onaran, Paola Molinari, Remo Guerrini, Gianfranco Balboni, Girolamo Calò, Tommaso Costa.   

Abstract

Using a cell-free bioluminescence resonance energy transfer strategy we compared the levels of spontaneous and ligand-induced receptor-G protein coupling in δ (DOP) and μ (MOP) opioid receptors. In this assay GDP can suppress spontaneous coupling, thus allowing its quantification. The level of constitutive activity was 4-5 times greater at the DOP than at the MOP receptor. A series of opioid analogues with a common peptidomimetic scaffold displayed remarkable inversions of efficacy in the two receptors. Agonists that enhanced coupling above the low intrinsic level of the MOP receptor were inverse agonists in reducing the greater level of constitutive coupling of the DOP receptor. Yet the intrinsic activities of such ligands are identical when scaled over the GDP base line of both receptors. This pattern is in conflict with the predictions of the ternary complex model and the "two state" extensions. According to this theory, the order of spontaneous and ligand-induced coupling cannot be reversed if a shift of the equilibrium between active and inactive forms raises constitutive activation in one receptor type. We propose that constitutive activation results from a lessened intrinsic barrier that restrains spontaneous coupling. Any ligand, regardless of its efficacy, must enhance this constraint to stabilize the ligand-bound complexed form.

Entities:  

Keywords:  Bioluminescence Resonance Energy Transfer (BRET); Constitutive Receptor Activation; Cooperativity; G Protein-coupled Receptors (GPCR); G Proteins; Inverse Agonism; Opiate Opioid

Mesh:

Substances:

Year:  2013        PMID: 23836900      PMCID: PMC3745342          DOI: 10.1074/jbc.M113.474452

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Energetics of ligand binding to proteins.

Authors:  G Weber
Journal:  Adv Protein Chem       Date:  1975

Review 2.  Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective.

Authors:  Graeme Milligan
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

3.  Complex ligand-protein systems: a globally convergent iterative method for the n x m case.

Authors:  J R Pradines; J Hasty; K Pakdaman
Journal:  J Math Biol       Date:  2001-10       Impact factor: 2.259

4.  Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.

Authors:  Gianfranco Balboni; Severo Salvadori; Remo Guerrini; Lucia Negri; Elisa Giannini; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2004-07-29       Impact factor: 7.446

5.  Ligand binding and internal equilibria in proteins.

Authors:  G Weber
Journal:  Biochemistry       Date:  1972-02-29       Impact factor: 3.162

6.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

7.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.

Authors:  A De Lean; J M Stadel; R J Lefkowitz
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

8.  Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor.

Authors:  Michael Zocher; Juan J Fung; Brian K Kobilka; Daniel J Müller
Journal:  Structure       Date:  2012-06-28       Impact factor: 5.006

9.  The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland.

Authors:  K A Wreggett; A De Léan
Journal:  Mol Pharmacol       Date:  1984-09       Impact factor: 4.436

10.  Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism.

Authors:  Gianfranco Balboni; Severo Salvadori; Remo Guerrini; Lucia Negri; Elisa Giannini; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus
Journal:  Bioorg Med Chem       Date:  2003-12-01       Impact factor: 3.641

View more
  13 in total

1.  Latent sensitization: a model for stress-sensitive chronic pain.

Authors:  Juan Carlos Marvizon; Wendy Walwyn; Ani Minasyan; Wenling Chen; Bradley K Taylor
Journal:  Curr Protoc Neurosci       Date:  2015-04-01

Review 2.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 3.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

4.  The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist.

Authors:  M M Gassaway; M-L Rives; A C Kruegel; J A Javitch; D Sames
Journal:  Transl Psychiatry       Date:  2014-07-15       Impact factor: 6.222

5.  Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.

Authors:  Dean P Staus; Ryan T Strachan; Aashish Manglik; Biswaranjan Pani; Alem W Kahsai; Tae Hun Kim; Laura M Wingler; Seungkirl Ahn; Arnab Chatterjee; Ali Masoudi; Andrew C Kruse; Els Pardon; Jan Steyaert; William I Weis; R Scott Prosser; Brian K Kobilka; Tommaso Costa; Robert J Lefkowitz
Journal:  Nature       Date:  2016-07-13       Impact factor: 49.962

6.  In Vitro Effects of the Endocrine Disruptor p,p'-DDT on Human Follitropin Receptor.

Authors:  Mathilde Munier; Julie Grouleff; Louis Gourdin; Mathilde Fauchard; Vanessa Chantreau; Daniel Henrion; Régis Coutant; Birgit Schiøtt; Marie Chabbert; Patrice Rodien
Journal:  Environ Health Perspect       Date:  2016-02-19       Impact factor: 9.031

7.  Vasopressin receptor 2 mutations in the nephrogenic syndrome of inappropriate antidiuresis show different mechanisms of constitutive activation for G protein coupled receptors.

Authors:  Vanessa Vezzi; Caterina Ambrosio; Maria Cristina Grò; Paola Molinari; Gökçe Süral; Tommaso Costa; H Ongun Onaran; Susanna Cotecchia
Journal:  Sci Rep       Date:  2020-06-04       Impact factor: 4.379

8.  The Meta-Position of Phe4 in Leu-Enkephalin Regulates Potency, Selectivity, Functional Activity, and Signaling Bias at the Delta and Mu Opioid Receptors.

Authors:  Robert J Cassell; Krishna K Sharma; Hongyu Su; Benjamin R Cummins; Haoyue Cui; Kendall L Mores; Arryn T Blaine; Ryan A Altman; Richard M van Rijn
Journal:  Molecules       Date:  2019-12-12       Impact factor: 4.411

9.  Sustained Suppression of Hyperalgesia during Latent Sensitization by μ-, δ-, and κ-opioid receptors and α2A Adrenergic Receptors: Role of Constitutive Activity.

Authors:  Wendy M Walwyn; Wenling Chen; Hyeyoung Kim; Ani Minasyan; Helena S Ennes; James A McRoberts; Juan Carlos G Marvizón
Journal:  J Neurosci       Date:  2016-01-06       Impact factor: 6.167

10.  Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2.

Authors:  D Malfacini; C Ambrosio; M C Gro'; M Sbraccia; C Trapella; R Guerrini; M Bonora; P Pinton; T Costa; G Calo'
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.